Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-10-01 18:44:11 - browse：2

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Ahead of JPM, here's who's profiting most in health care

knowledge

hotspot

WSS

Type 2 diabetes prevention programs work at large scale: study

The biotech scorecard for Q1: 17 stock

First transplant of an entire human eye performed

3 medical device trends to watch in 2024

3 trends to watch in health tech's hiring outlook for 2024

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

hotspot

Wikipedia

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

Feng Zhang CRISPR delivery startup lays off quarter of staff

State Dept. review finds Biden bears some blame for Afghanistan failures

GSK Flovent asthma inhalers replaced by authorized generics

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

New weight loss drugs work. But how can they best be used?

What does generative AI mean for health care? We asked experts

After decades in use, heart stents finally beat placebo

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

focus

Study suggests Covid rebound is far more common with Paxlovid than without

Feng Zhang CRISPR delivery startup lays off quarter of staff

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Ahead of JPM, here's who's profiting most in health care

What is STAT's opinion section for?

Wikipedia

knowledge

hotspot

leisure time